Identification of empagliflozin-related hub genes in atherosclerosis and their correlations with immune infiltration: Network pharmacology and bioinformatics analyses. [PDF]
PLoS OneRong Y, Liu X, Sun Y, Yang L, Chen L.
europepmc +1 more source
A network meta-analysis of safety and efficacy of sodium-glucose cotransporter 2 inhibitors in heart failure patients. [PDF]
Ann Med Surg (Lond)Abuhashem S +8 more
europepmc +1 more source
Effectiveness and Safety of Fixed-Dose Empagliflozin/Linagliptin Combination in Type 2 Diabetes Mellitus: Real-World Evidence From Bangladesh. [PDF]
CureusPrasad I +9 more
europepmc +1 more source
To investigate the effect of a high-fat diet on pharmacokinetics/renal function/RAAS-related parameters after a single dose of empagliflozin in healthy Chinese adults. [PDF]
BMC Pharmacol ToxicolJin Y +8 more
europepmc +1 more source
Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial. [PDF]
Diabetes Obes MetabLee SH +15 more
europepmc +1 more source
Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled. [PDF]
JACC AdvDhingra NK +13 more
europepmc +1 more source
Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study. [PDF]
BMC Endocr DisordKiran Z +5 more
europepmc +1 more source
Clinical Outcomes and Management in Late Diagnosed Siblings Affected With Attenuated GSD Ib. [PDF]
JIMD RepLynch G +5 more
europepmc +1 more source
Feasibility Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease: Design and Baseline Characteristics. [PDF]
Am J NephrolSeliger SL +10 more
europepmc +1 more source
SGLT2 Inhibitors and Long-Term Outcomes After AKI. [PDF]
Kidney Int RepWannakittirat A +9 more
europepmc +1 more source